Chronic Hepatitis B Monitoring and Treatment Patterns in Five European Countries with Different Access and Reimbursement Policies
Antiviral Therapy2013Vol. 19(3), pp. 245–257
Citations Over TimeTop 15% of 2013 papers
Victoria Aramă, Hakan Leblebicioğlu, Krzysztof Simon, Jean Pierre Zarski, Claus Niederau, François Habersetzer, Johannes Vermehren, Wiesława Błudzin, Mariana Jinga, Sercan Ulusoy, Isabelle Klauck, Edith Morais, Stefan Bjork, Bénédicte Lescrauwaet, Driss Kamar, S Zeuzem, the AI463-121 European Longitudinal Chronic Hepatitis B Study Group, Patrick Marcellin, Danielle Botta‐Fridlund, Stanislas Pol, M. Travis Maynard, François Habersetzer, Xavier Causse, Laurent Alric, Pauline Simo Noumbissie, Stefan Mauss, Guido Gerken, Tobias Goeser, Manfred Wiese, Heiner Busch, Lothar Schneider, Jens Schubert, Meike Brenner, Inka Scheffrahn, Andrzej Dziambor, Dariusz Goryszewski, Barbara Postawa-Kłosińska, Jerzy Sieklucki, Robert Pleśniak, Monica Acalovschi, C Tănăsescu, Lucian Raducan, Ioan Sporea, M Voiculescu, Olimpia Chira, Sorin Ștefan Aramă, Mihaela Rădulescu, Adriana Nicolau, Doina Niţescu, Daniel Munteanu, Andrei Nanu, Isabel Dan, Diana Nicoliţă, Camelia Ionescu, Monica Ecobici, Gina Micu, Raluca Irinel Parepa, Andra‐Iulia Suceveanu, Gaye Usluer, Mevlüt Başkol, Reşat Özaras, Şaban Esen, Elif Doyuk Kartal, Tansu Yamazhan
Abstract
These results illustrate country-specific patterns in the management of CHB patients across Europe. Observed monitoring patterns, hospitalization rates and other health-care utilization may be related to cost and reimbursement issues; however, further study in individual countries would be required to confirm these (post hoc) observations.
Related Papers
- → Selection of an entecavir-resistant mutant despite prolonged hepatitis B virus DNA suppression, in a chronic hepatitis B patient with preexistent lamivudine resistance: successful rescue therapy with tenofovir(2008)25 cited
- → Randomized trial of lamivudine versus entecavir in entecavir-treated patients with undetectable hepatitis B virus DNA: Outcome at 2 Years(2011)14 cited
- → Lamivudine-to-entecavir switching treatment in type B chronic hepatitis patients without evidence of lamivudine resistance(2009)13 cited
- → The Comparative Efficacy and Safety of Entecavir and Lamivudine in Patients with HBV-Associated Acute-on-Chronic Liver Failure: A Systematic Review and Meta-Analysis(2016)5 cited
- → The High Incidence of the Emergence of Entecavir-Resistant Mutants among Patients Infected with Lamivudine-Resistant Hepatitis B Virus(2007)9 cited